8:20 am Chair’s Opening Remarks
- Shelley Ackerman Associate Director & Project Team Lead, Bolt Biotherapeutics
Going Beyond ‘Traditional’ Antibody Formats Delving into Non-MAb Based Scaffolds
8:30 am Sharing Aptamer-Drug Conjugates (ApDC’s): Using the “Chemical Antibody” to Target Cancer Biomarkers & Kill Tumor Cells
- Christina McGuire Senior Scientist, Guardian Therapeutics
- Identification and optimization of nuclease stable, fully modified 2’OMethyl RNA aptamers that recognize cancer biomarkers with high affinity and specificity through a process called SELEX.
- A review of the chemical advantages of aptamers over antibodies for developing drug conjugates and the synthesis of aptamer-drug conjugates.
- Selective in vitro and in vivo killing of cancer cells using ApDC’s.
9:00 am Developing Pan-tumoral Small Molecule-Drug Conjugates Targeting Fibroblast Activation Protein in Solid Lesions
- Andrea Galbiati Research Scientist, Philochem
- OncoFAP is a clinically validated small organic ligand targeting FAP in solid tumors
- Examine how OncoFAP-drug conjugates selectively target tumors in vivo and release high amount of MMAE at the site of disease
- Investigate how OncoFAP-drug conjugates potently induce an anti-tumor response at doses below tumor saturation both in monotherapy and in combination with immunotherapy
9:30 am A Novel Molecular Drug Delivery System Based on Peptide-Drug Conjugates
- Yi-Shen Zhu Professor, Nanjing Tech University
- A single peptide–drug conjugate molecule achieves multiple biological functions, which is proposed as molecular drug delivery system.
- Peptide–drug conjugates have been introduced as potential diagnostics and anticancer drugs in the clinic.
- Oral administration is very important to promote the development of peptide– drug conjugate molecular drug delivery systems
10:00 am Probing-to-Perturbing: Image- Guided Controlled Drug Release In Vivo
- Zhibo Lui Principal Investigator, Peking University
- Evaluate image-guided in vivo desilylation cleavage chemistry and its use in ADC
- Assess local proptosis induced by in vivo desilylation heats tumor immunity
- Examine radiotherapy-activated controlled drug release in tumors
Morning Refreshments & Networking
Conjugation Challenges of Novel Format Drug Conjugates
11:30 am Exploring VIP236, an avß3-Integrin-targeted Small Molecule Drug Conjugate with a Tailored Design of Linker & Metabolite Profile
- Hans Georg Lerchen Chief Scientific Officer, Vincerx Pharma
- avß3-integrin targeted SMDC for the treatment of multiple cancer types
- Reviewing linker design for efficient cleavage by tumor associated neutrophil elastase
- Assessing a modified camptothecin payload with high permeability and low efflux ratio
12:00 pm Delving into Antibody Fragment Drug Conjugates (FDCs): Building a Platform to Harness the Power of Penetration
- Mahendra Deonorain Chief Executive Officer, Chief Science & Operating Officer, Antikor Biopharma
- Why haven’t antibody fragments such as scFvs and Fab made good drug conjugate products, until now?
- Designing and using antibody libraries specifically for bio-conjugation
- Examples of FDC products that can compete and out-perform conventional ADC in preclinical models of cancer
12:30 pm Bispecific XDC – A Versatile Drug Delivery Platform
- Robert Huang Founder & Chief Executive Officer, Coherent Biopharma
- Exploring design features of a bispecific XDC
- Providing a clinical overview of CBP-1008
- Discussing bispecific XDC as a versatile drug delivery platform
1:00 pm Targeted C’Dot Drug Conjugates (CDCs). An Ultra-Small Delivery Platform That Addresses Limitations of ADCs
- Gregory Adams Chief Scientific Officer, Elucida Oncology Inc.
- CDCs ultra-small 6-7 nM size facilitates deeper tumor penetration and delivery to difficult to target tumors including those in the brain coupled with rapid systemic elimination which can enhance therapeutic efficacy with decreased off-target toxicities.
- The unique chemistry of the platform allows for the attachment of up to 80 payload molecules and targeting moieties to each C’Dot resulting in CDCs with high potency and avidity.
- Preclinical and nonclinical toxicology/TK data from ELU001 – Elucida’s anti-folate receptor alpha C’Dot with a topoisomerase-1 inhibitor payload which is currently in a phase 1 trial – will be discussed.
Lunch & Networking
Sharing Novel Technologies for STING/TLR Payloads
2:30 pm PD-L1 ISACs elicit superior anti-tumor activity over PD-L1 mAbs: the benefit of ISAC-driven phagocytosis and direct activation of PD-L1-expressing myeloid cells
- Michael Alonso Vice President of Immunology & Pharmacology, Bolt Biotherapeutics
- Overview of Bolt’s Immune-Stimulating Antibody Conjugates (ISAC) technology platform as the next step in ADC-based immune therapy
- Highlighting the key features and the mechanism of action
- Demonstrating the use of various methods to understand and design potent ISACs
Exploring the Current Alternative Payload Landscape & New Developments
3:00 pm Demonstrating How FORCETM Platform Delivers Multiple Payload Types, Tailored to Treat Serious Muscle Diseases
- Timothy Weeden Senior Director & Head of Platform Development, Dyne Therapeutics
- FORCE Platform (target, high level structure, manufacturability and —Drug:Ab control)
- Review modularity of payload types
- Analyze potency across different disease models
3:30 pm Exploring Next Generation Drug Conjugates
- Jarrod Longcor Chief Business Officer & SVP of Operations, Cellectar Biosciences
- Discover how PLEs represent a new class of drug conjugates using multiple therapeutic classes of payloads
- Highlighting how the unique MoA facilitates killing of primary tumor cells, metastatic cells and CSCs and offers new treatment options for difficult to treat and refractory cancers
- Examining how broad and versatile the potential of the PLE platform can be for treatment of different cancers
Understanding Target Engagement of Novel Formats
4:30 pm SORT1+ TechnologyTM Platform & Novel Peptide Drug Conjugates (PDC’s) Targeting Sortilin (SORT1)
- Christian Marsolais Chief Medical Officer & Vice President of Medical Affairs, Theratechnologies
- Learn about the Sortilin receptor, its role in the normal cell and how its role and function change in cancer
- Understand why sortilin is an important biomarker/target in cancer, it expression levels in solid tumors, how it can be used for novel drug delivery and why it is an ideal candidate for internalization of novel peptide drug conjugates (PDC’s)
- Evaluate Sortilin’s unique structure and MOA, leading to rapid internalization into the cancer cells and delivery of less toxic payloads with better efficacy and safety profiles. Preclinical data will be discussed to demonstrate the efficacy and safety of Thera’s lead PDC candidate, TH1902, across multiple solid tumors and an update on the ongoing clinical FIH trial will be given.
- Review the potential of this novel SORT1+ platform for future developments
5:00 pm Simultaneous Treatment of Primary Solid Tumors, Metastatic Sites, & Tumor-draining Lymph Nodes Using a Non-traditional ADC to Target High Endothelial Venules
- Cari Meisel Director of Research & Development, NanoTomer
- Overview of HEVs as a novel, non-traditional target with a unique mechanism of action and strong therapeutic potential
- Evaluating concerns about off-target binding and toxicity
- Discussion of challenges and benefits of developing an IgM-format ADC
5:30 pm Chair’s Closing Remarks
- Gavin Bennet Head of Pre-Clinical Development, Bicycle Therapeutics